The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 23 August 2005, www.theannals.com, DOI 10.1345/aph.1G069.
 The Annals of Pharmacotherapy: Vol. 39, No. 10, pp. 1714-1718. DOI 10.1345/aph.1G069
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Irons, B. K
Right arrow Articles by Kroon, L. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Irons, B. K
Right arrow Articles by Kroon, L. A

DIABETES

Lipid Management with Statins in Type 2 Diabetes Mellitus

Brian K Irons, PharmD BCPS1, and Lisa A Kroon, PharmD CDE2

1 Division Head, Primary Care, Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX
2 Associate Professor of Clinical Pharmacy, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA

Reprints: Dr. Irons, TTUHSC—School of Pharmacy, 3601 4th St., Ste. 1C162, Lubbock, TX 79430-8162, fax 806/743-4209, brian.irons{at}ttuhsc.edu

Abstract

OBJECTIVE: To provide an update on lipid management and recent modifications in cholesterol guidelines for use of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), specifically in patients with diabetes.

DATA SOURCES: Studies and guidelines were identified through a MEDLINE search (1996-April 2005).

STUDY SELECTION AND DATA EXTRACTION: Studies were selected for review if the primary treatment intervention was a statin, at least 4% of the study population held a diagnosis of diabetes, and diabetes subgroup analysis was available.

DATA SYNTHESIS: The Heart Protection Study demonstrated an approximately 25% relative risk reduction of a first coronary event in patients with diabetes, a reduction similar to those without diabetes. In subjects with diabetes, a significant reduction in coronary events was noted regardless of the baseline cholesterol level. The Collaborative Atorvastatin Diabetes Study demonstrated a 37% relative risk reduction in the primary prevention of cardiovascular morbidity in patients with diabetes.

CONCLUSIONS: Based on the current literature, a low-density lipoprotein cholesterol (LDL-C) level <100 mg/dL remains an appropriate goal for patients with diabetes in the absence of established cardiovascular disease. For higher-risk patients, such as those with diabetes and a history of cardiovascular disease, a more stringent LDL-C goal of <70 mg/dL is an option according to current clinical trial evidence. At least a 30-40% reduction in the LDL-C level is advisable when initiating statin therapy.

Key Words: diabetes, lipids, statins

Published Online, August 23, 2005. www.theannals.com, DOI 10.1345/aph.1G069

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-030-H01




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.